Predictors of optimal virological response to potent antiretroviral therapy von POWDERLY, W. G, SAAG, M. S, CHAPMAN, S, YU, G, QUART, B, CLENDENINN, N. J

Volltext

Polyglutamation of methotrexate: is methotrexate a prodrug? von CHABNER, B. A, ALLEGRA, C. J, CURT, G. A, CLENDENINN, N. J, BARAM, J, KOIZUMI, S, DRAKE, J. C, JOLIVET, J

Volltext

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration von Jodrell, D I, Bowman, A, Rye, R, Byrne, B, Boddy, A, Rafi, I, Taylor, G A, Johnston, A, Clendeninn, N J

Volltext

The Pharmacology and Clinical Use of Methotrexate von Jolivet, Jacques, Cowan, Kenneth H, Curt, Gregory A, Clendeninn, Neil J, Chabner, Bruce A

Volltext

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder von KHORSAND, M, LANGE, J, FEUN, L, CLENDENINN, N. J, COLLIER, M, WILDING, G

Volltext

Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion von O'DWYER, P. J, LAUB, P. B, GALLO, J. M, DEMARIA, D, QIAN, M, REILLY, D, GIANTONIO, B, JOHNSTON, A. L, WU, E. Y, BAUMAN, L, CLENDENINN, N. J

Volltext

Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration von FEUN, L. G, GONZALEZ, R, SAVARAJ, N, HANLON, J, COLLIER, M, ROBINSON, W. A, CLENDENINN, N. J

Volltext

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks von ROBERTS, J. D, SHIBATA, S, PARADISO, L. J, CLENDENINN, N. J, SPICER, D. V, MCLEOD, H. L, TOMBES, M. B, KYLE, B, CARROLL, M, SHEEDY, B, COLLIER, M. A, PITHAVALA, Y. K

Volltext

Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma von FEUN, L. G, ROBINSON, W. A, SAVARAJ, N, GONZALEZ, R, LIEBMANN, A, OFFENHAUSER, K, CLENDENINN, N. J

Volltext

Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: A feasible and active approach von Vokes, E. E., Haraf, D. J., McEvilly, J. M., Mick, R., Kozloff, M. F., Goldman, M. D., Moran, W. J., Clendeninn, N. J., Collier, M. A., selbaum, R. R. Weich, Panje, W. R.

Volltext

Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule von ADAMSON, P. C, BALIS, F. M, MISER, J, ARNDT, C, WELLS, R. J, GILLESPIE, A, ARONSON, L, PENTA, J. S, CLENDENINN, N. J, POPLACK, D. G

Volltext

Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate von CURT, G. A, JOLIVET, J, CARNEY, D. N, BAILEY, B. D, DRAKE, J. C, CLENDENINN, N. J, CHABNER, B. A

Volltext

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma von BERLIN, J, KING, A. C, TUTSCH, K, FINDLAY, J. W, KOHLER, P, COLLIER, M, CLENDENINN, N. J, WILDING, G

Volltext

Phase I Trial of Piritrexim Capsules Using Prolonged, Low-Dose Oral Administration for the Treatment of Advanced Malignancies von Feun, Lynn G., Savaraj, Niramol, Benedetto, Pasquale, Hanlon, James, Sridhar, Kasi S., Collier, Mary, Richman, Stephen, Liao, Sam H., Clendeninn, Neil J.

Volltext

Oral piritrexim : a phase II study in patients with advanced soft tissue sarcoma von SCHIESEL, J. D, CARABASI, M, MAGILL, G, CASPER, E, CHENG, E, MARKS, L, FEYZI, J, CLENDENINN, N. J, SMALLEY, R. V

Volltext

A phase II study of piritrexim in patients with advanced squamous head and neck cancer von Uen, Wu‐Ching, Huang, Andrew T., Mennel, Robert, Jones, Stephen E., Spaulding, Monica B., Killion, Kathleen, Havlin, Kathleen, Keegan, Patricia, Clendeninn, Neil J.

Volltext

Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion von SCHILSKY, R. L, RATAIN, M. J, JANISCH, L, VOGELZANG, N. J, SOL LUCAS, V, RAVITCH, J, HOHNEKER, J. A, CLENDENINN, N. J, TUTTLE, R. L

Volltext

Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer von Gore, L., Lewis, K., Von Hoff, D. D., Weiss, G. J., Ramanathan, R. K., Adjei, A. A., Dy, G. K., Ma, W. W., Clendeninn, N. J., Leffingwell, D. P., Sheedy, B., Iverson, C., Miner, J. N., Shen, Z., Yeh, L., Dubowy, R. L., Jeffers, M., Rajagopalan, P., Weekes, C. D.

Volltext

Initial clinical trial and pharmacokinetics of Thymitaq (AG337) by 10-day continuous infusion in patients with advanced solid tumors von Creaven, P J, Pendyala, L, Meropol, N J, Clendeninn, N J, Wu, E Y, Loewen, G M, Proefrock, A, Johnston, A, Dixon, M

Volltext

A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer von Vokes, Everett E., Dimery, Isaiah W., Jacobs, Charlotte D., Karp, Daniel, Molina, Arturo, Collier, Mary A., Eble, Melody L., Clendeninn, Neil J.

Volltext